The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).
 
Panagiotis J. Vlachostergios
Honoraria - Dava Oncology
 
Muhammad Junaid Niaz
No Relationships to Disclose
 
Seyed Ali Mosallaie
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Amy Hackett
No Relationships to Disclose
 
Joseph R. Osborne
No Relationships to Disclose
 
Yuliya Jhanwar
No Relationships to Disclose
 
Lauren Gracey
No Relationships to Disclose
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Neil Harrison Bander
Stock and Other Ownership Interests - BZL Biologics
Consulting or Advisory Role - ADC Therapeutics; BZL Biologics; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Patents to anti-PSMA antibodies assigned to Cornell Univ; Royalty--Cook Urological
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi